R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
Completed
University of Miami
Phase 2
2004-04-01
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with
thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy followed by thalidomide works in treating patients with previously untreated
mantle cell lymphoma.
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
Completed
Allergan
Phase 1/Phase 2
2010-03-01
This study will evaluate the safety and efficacy of a single intravitreal injection of
AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being
conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a
single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of
AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2
will enroll approximately 96 subjects who will receive a single masked intravitreal injection
of one of three doses of AGN208397 or Ozurdex® and be followed for 12 months post treatment.
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
Terminated
Allergan
Phase 2
2010-08-01
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive
therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of
patients with choroidal neovascularization secondary to age-related macular degeneration
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Completed
Long Island Vitreoretinal Consultants
N/A
2010-09-01
The purpose of this study is to compare visual improvement and total number of intraocular
injections in eyes with macular edema following central retinal vein occlusion (CRVO)after
initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
